LifeStance Health Group, Inc. (LFST)

Investigation 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of LifeStance Health Group, Inc. ("LifeStance” or the "Company") (NASDAQ: LFST). The investigation concerns whether LifeStance and certain of its officers and/or directors have violated federal securities laws.

 

On or around June 10, 2021, LifeStance sold approximately 40 million shares of stock in its initial public stock offering (the “IPO”) at $18 a share, raising nearly $720 million in new capital.  On August 11, 2021, LifeStance released its financial results for the second quarter of 2021, reporting a net loss of $70 million.  On this news, LifeStance’s stock price fell $10.16 per share, or 46.46%, to close at $11.71 per share on August 12, 2021.  Then, on November 8, 2021, LifeStance released its financial results for the third quarter of 2021, reporting a net loss of $120.5 million compared to a net loss of only $3.3 million for the same period in the prior year.  On this news, LifeStance’s stock price fell sharply during intraday trading on November 9, 2021.

 

If you are aware of any facts relating to this investigation, or purchased LifeStance shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.